CSS
ABUS icon

Cubist Systematic Strategies’s Arbutus Biopharma ABUS Stock Holding History

Cubist Systematic Strategies’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,192
Closed -$18K – 3631
2023
Q4 		$18K Buy
+7,192
New +$14.1K ﹤0.01% 3360
2023
Q2 		– Sell
-119,193
Closed -$361K – 3409
2023
Q1 		$361K Buy
+119,193
New +$336K ﹤0.01% 2866
2022
Q4 		– Sell
-10,726
Closed -$20K – 4188
2022
Q3 		$20K Sell
10,726
-30,021
-74% -$70.7K ﹤0.01% 4242
2022
Q2 		$110K Sell
40,747
-154,717
-79% -$396K ﹤0.01% 3943
2022
Q1 		$582K Sell
195,464
-68,124
-26% -$209K ﹤0.01% 2437
2021
Q4 		$1.02M Buy
263,588
+249,988
+1,838% +$971K 0.01% 1895
2021
Q3 		$58K Sell
13,600
-50,100
-79% -$167K ﹤0.01% 2821
2021
Q2 		$193K Sell
63,700
-121,815
-66% -$377K ﹤0.01% 2577
2021
Q1 		$618K Buy
185,515
+134,616
+264% +$519K 0.01% 1839
2020
Q4 		$181K Buy
+50,899
New +$178K ﹤0.01% 2272
2020
Q3 		– Sell
-12,562
Closed -$23K – 2464
2020
Q2 		$23K Buy
+12,562
New +$20.6K ﹤0.01% 2310
2020
Q1 		– Sell
-895
Closed -$2K – 2128
2019
Q4 		$2K Buy
+895
New +$1.45K ﹤0.01% 2385
2017
Q4 		– Sell
-300
Closed -$2K – 1877
2017
Q3 		$2K Buy
+300
New +$1.28K ﹤0.01% 1810
2015
Q3 		– Sell
-1,634
Closed -$19K – 1838
2015
Q2 		$19K Buy
1,634
+1,534
+1,534% +$23.3K ﹤0.01% 1756
2015
Q1 		$2K Buy
+100
New +$2.05K ﹤0.01% 1859

Other funds holding ABUS

WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cubist Systematic Strategies's ABUS Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of Arbutus Biopharma (ABUS) in Q1 2024, closing a stake of 7,192 shares — an estimated $18K sold.

Cubist Systematic Strategies first reported a position in ABUS in Q1 2015 and held it in 15 quarters. The position peaked at $1.02M in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining Arbutus Biopharma position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 7,192 Arbutus Biopharma shares in Q1 2024, an estimated $18K.
  • Cubist Systematic Strategies first reported a position in Arbutus Biopharma in Q1 2015 and held it in 15 quarters.
  • Cubist Systematic Strategies's Arbutus Biopharma position peaked at $1.02M in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.